Pei-Chang Wu1, Hsi-Kung Kuo, Ming-Hong Tai, Shyi-Jang Shin. 1. Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Abstract
PURPOSE: To report a case of impending recurrent pterygium treated with topical bevacizumab eyedrops. METHODS: A 53-year-old woman with impending recurrent pterygium was treated with topical bevacizumab eyedrops (25 mg/mL) administered 4 times daily for 3 weeks. Two months previously, she had undergone excision of a primary ptergyium in the same eye by bare sclera recision and application of mitomycin C. RESULTS: Treatment with topical bevacizumab for 3 weeks produced prominent regression of limbal-conjunctival neovascularization. At 6-month follow-up, no recurrent pterygium was noted. Symptoms were resolved with no ocular irritation, burning, or any systemic adverse effects. CONCLUSIONS: These data suggest that off-label short-term use of topical bevacizumab may be effective to prevent recurrence in a patient with impending recurrent pterygium. We believe that this is the first known successful use of topical bevacizumab in such a patient.
PURPOSE: To report a case of impending recurrent pterygium treated with topical bevacizumab eyedrops. METHODS: A 53-year-old woman with impending recurrent pterygium was treated with topical bevacizumab eyedrops (25 mg/mL) administered 4 times daily for 3 weeks. Two months previously, she had undergone excision of a primary ptergyium in the same eye by bare sclera recision and application of mitomycin C. RESULTS: Treatment with topical bevacizumab for 3 weeks produced prominent regression of limbal-conjunctival neovascularization. At 6-month follow-up, no recurrent pterygium was noted. Symptoms were resolved with no ocular irritation, burning, or any systemic adverse effects. CONCLUSIONS: These data suggest that off-label short-term use of topical bevacizumab may be effective to prevent recurrence in a patient with impending recurrent pterygium. We believe that this is the first known successful use of topical bevacizumab in such a patient.
Authors: D G Said; L A Faraj; M S Elalfy; A Yeung; A Miri; U Fares; A M Otri; I Rahman; S Maharajan; H S Dua Journal: Eye (Lond) Date: 2013-06-28 Impact factor: 3.775
Authors: Ruth Lapid-Gortzak; Nathalie T Y Santana; Carla P Nieuwendaal; Maarten P Mourits; Ivanka J E van der Meulen Journal: Int Ophthalmol Date: 2017-06-15 Impact factor: 2.031